ArticleMovement disorders clinical practice2026
Use of the PROMIS and Neuro-QoL to Evaluate Health-Related Quality of Life following Unilateral Subthalamic Deep Brain Stimulation for Parkinson's Disease.
Article in Movement disorders clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundSubthalamic nucleus deep brain stimulation (STN DBS) improves Parkinson's disease (PD)-related motor symptoms, but how STN DBS impacts various aspects of patient-perceived health-related quality of life (HRQoL) is less clear. The Patient-Reported Outcome Measurement Instrument (PROMIS) and Quality of Life in Neurological Disorders (Neuro-QoL), National Institutes of Health computer adaptive inventories, are T-scored to a normative reference sample, and assesses 16 domains of a patient's HRQoL.
objectivesThis cross-sectional study evaluated the convergent validity of a novel PROMIS + Neuro-QoL aggregate measure, the construct validity of the aggregate and 16 PROMIS and Neuro-QoL domains, and the responsiveness of these measures to change after STN DBS.
methodsTwenty eight people with PD completed the PROMIS, Neuro-QoL, Parkinson's disease Questionnaire-8 (PDQ-8), and the Movement Disorder Society Unified Parkinson's Disease Rating Scale part III before surgery for STN DBS and at two follow-up visits within 6 months after surgery. A Pearson correlation assessed the relationship between PROMIS + Neuro-QoL aggregate and the PDQ-8, to determine convergent validity. One-sample t tests compared preoperative scores to normative means. Finally, one-sample t tests compared preoperative HRQoL and HRQoL after STN DBS.
resultsThe PROMIS + Neuro-QoL aggregate agreed strongly with the PDQ-8, providing convergent validation. Preoperatively, patients reported significantly worse-than-normative values of overall HRQoL, physical function, cognitive function, social health, fatigue, and mental health, providing construct validation. After DBS, the PROMIS + Neuro-QoL aggregate, physical function, cognitive function, social health, and sleep improved, demonstrating responsiveness to change of the PROMIS and Neuro-QoL.
conclusionsOverall, these findings support the potential integration of the PROMIS and Neuro-QoL in clinical and research settings in patients with PD to provide valuable insights into the patient's lived experience during DBS therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.